Since their incorporation in October 2015, one of IBPL’s major research activity has been the fermentation of the bacterium – Haemophilus influenzae B (HIB) – for production of extracellular polysaccharide, which is a major constituent of vaccines such as meningococcal vaccine.
They have also been working on two separate projects: The first is a project offered by Dhampur Sugar Mills on membrane cell recycle continuous fermentation of dilute molasses to ethanol. This work is now nearing completion, and is expected to have an impact on minimizing the effluent of molasses fermentation, which is a priority for improving pollution control in the alcohol distillation industry.
In October 2016, they were also granted a project by SBIRI (BIRAC) for work on the Human Papilloma Virus vaccine using a recombinant yeast for production of Virus like particles (VLPs) that can be used in the manufacture of the quadrivalent vaccine against HPV. This is a dire need of the country as more than 270 million adolescent women/girls are at risk of cervical cancer against which the vaccine works.
Biolmed is a spin-off based on NCL ‘s technology created under Venture Center’s “Lab2Mkt” program. The start-up aim to develop biomedical products for healthcare applications for human bone defects like bony voids, long bone defects and traumatic /surgical osseous defects. The company’s first product will be a osteoconductive bone graft substitute kit based on the silk-fibroin material. Biolmed has received Biotechnology Ignition Grant by DBT-BIRAC, GoI
VIVIRA is a spin-off based on NCL’s technology. The Start–up plans to develop a novel and patent protected vortex diode based cavitation device (VodCa®) for enhancing bio-gas yield and throughput of anaerobic digesters. In-particular, prove the concept for biological digesters used in distillery industries (enhance throughput per m3 of digester and gas yield per m3 of spent wash by 20%). The technology has applications in several agri- and marine- biotech industries.
Actorius Innovations and Research Pvt Ltd (AIR) is a research and development company focused on creating novel biomaterials that have critical applications in the life science, drug delivery and medical diagnostics field. The company strives to develop in-house platform technologies that will fulfill a current need in medical procedure by improving upon an existing technology or device, or an unmet need that is clearly defined and acknowledged by medical professionals. AIR is founded by Dr. Jayant Khandare who is an NCL alumnus and Ex-Piramal Life Sciences, Dr. Muralidhara Padigaru who is also an ex-Piramal Life Sciences and Ph.D from PGIMER, Chandigarh. The third co-founder of AIR is Arvindan Vasudevan who has Master’s degree in Chemistry and a Certificate in Business Studies (Marketing).
AIR has received Biotechnology Ignition Grant and Small Business Innovation Research Initiative (SBIRI) grant by DBT-BIRAC, GoI.
Founded in 2010, Shantani Proteome Analytics Pvt. Ltd. is a privately-held biotechnology company that provides novel chemical-proteomics based technologies and services to identify & validate drug targets; thus de-risking molecules and supporting crucial GO / NO-GO decisions throughout the drug discovery process. The company has received SPARSH and SBIRI grant by DBT-BIRAC , GoI. The company has also raised early stage seed capital and angel funding. Shantani is founded by Dr. Chaitanya Saxena who is a seasoned professional and bring successful experience of developing technologies for drug-target deconvolution and drug-target interaction measurements in intact biological systems from his tenure at Eli Lilly & Company. Chaitanya earned a Ph.D. from The Ohio State University, Columbus, OH, USA.